Published in Can J Neurol Sci on May 01, 2008
Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 5.10
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis (2010) 1.70
Prospects for minocycline neuroprotection. Arch Neurol (2010) 1.27
Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07
Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice. Am J Pathol (2010) 0.94
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
11C-(R)-PK11195 PET imaging of microglial activation and response to minocycline in zymosan-treated rats. J Nucl Med (2011) 0.88
Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci (2009) 0.88
Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline. Graefes Arch Clin Exp Ophthalmol (2011) 0.85
Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation (2013) 0.82
Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma. Graefes Arch Clin Exp Ophthalmol (2014) 0.80
Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab (2016) 0.77
New oral disease-modifying therapies for multiple sclerosis. F1000 Med Rep (2009) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem (2002) 2.37
Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol (2012) 2.25
Reliability of assessing percentage of diffusion-perfusion mismatch. Stroke (2003) 2.22
The promise of minocycline in neurology. Lancet Neurol (2004) 2.06
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 2.00
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain (2012) 1.90
Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain (2003) 1.81
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility. J Biol Chem (2002) 1.73
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain (2003) 1.67
iPhone-based teleradiology for the diagnosis of acute cervico-dorsal spine trauma. Can J Neurol Sci (2010) 1.67
A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci (2004) 1.66
IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain (2004) 1.61
A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails. J Am Coll Cardiol (2012) 1.59
White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci (2007) 1.54
Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology (2002) 1.52
A quantitative analysis of suspected environmental causes of MS. Can J Neurol Sci (2011) 1.47
Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci (2003) 1.45
Treatment optimization in multiple sclerosis. Can J Neurol Sci (2004) 1.44
Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. J Neurosci Res (2008) 1.42
Quantitative assessment of carotid plaque composition using multicontrast MRI and registered histology. Magn Reson Med (2003) 1.41
MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol (2007) 1.36
Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J Neurosci (2009) 1.35
An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci (2003) 1.34
Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol (2003) 1.33
An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage (2009) 1.32
Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci (2006) 1.25
MR perfusion and diffusion in acute ischemic stroke: human gray and white matter have different thresholds for infarction. J Cereb Blood Flow Metab (2005) 1.25
Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol (2003) 1.24
Regional variation of multiple sclerosis prevalence in Canada. Mult Scler (2005) 1.22
Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol (2005) 1.18
Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci (2007) 1.18
An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J (2005) 1.18
Increased high-frequency oscillations precede in vitro low-Mg seizures. Epilepsia (2005) 1.17
Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res (2006) 1.16
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci (2003) 1.15
Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci (2013) 1.15
The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol (2013) 1.14
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci (2006) 1.11
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis. Glia (2012) 1.11
Image texture characterization using the discrete orthonormal S-transform. J Digit Imaging (2008) 1.11
Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry (2005) 1.10
Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J Neurosci (2006) 1.09
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol (2005) 1.09
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol (2004) 1.08
Remyelination therapy for multiple sclerosis. Neurotherapeutics (2013) 1.08
Psychotic disorders in MS: population-based evidence of an association. Neurology (2005) 1.06
EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci (2011) 1.06
Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Mol Immunol (2012) 1.06
A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis (2011) 1.05
Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol (2012) 1.05
Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice. Stroke (2009) 1.05
Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage. Brain (2008) 1.04
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain (2009) 1.03
Increased invasive capacity of connexin43-overexpressing malignant glioma cells. J Neurosurg (2003) 1.03
Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia (2007) 1.03
Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. Brain (2013) 1.03
Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A (2009) 1.02
Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol (2012) 1.02
Characterization of the early neuroinflammation after spinal cord injury in mice. J Neuropathol Exp Neurol (2007) 1.01
T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis. Neuroimage (2009) 1.01
Multiexponential T2 and magnetization transfer MRI of demyelination and remyelination in murine spinal cord. Neuroimage (2009) 1.01
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol (2012) 1.00
Human paragonimiasis in North America following ingestion of raw crayfish. Clin Infect Dis (2009) 0.99
The many faces of EMMPRIN - roles in neuroinflammation. Biochim Biophys Acta (2010) 0.99
Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation (2011) 0.98
Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol (2009) 0.98
Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. Glia (2013) 0.97
Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys Acta (2011) 0.97
Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med (2012) 0.96
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol (2006) 0.96
Matrix metalloproteinases in intracerebral hemorrhage. Neurol Res (2008) 0.95
Improving outcomes of neuroprotection by minocycline: guides from cell culture and intracerebral hemorrhage in mice. Am J Pathol (2010) 0.94
Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro. J Neuroimmunol (2008) 0.94
Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol (2007) 0.94
Validity of the Apple iPhone® /iPod Touch® as an accelerometer-based physical activity monitor: a proof-of-concept study. J Phys Act Health (2013) 0.94
The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis (2005) 0.94
Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol (2009) 0.93
The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis (2005) 0.93
The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler (2005) 0.92
Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin Chem Lab Med (2010) 0.91
Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am J Pathol (2009) 0.91
Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol (2005) 0.90
Environmental factors and their regulation of immunity in multiple sclerosis. J Neurol Sci (2012) 0.90
Prevalence of multiple sclerosis in First Nations people of Alberta. Can J Neurol Sci (2007) 0.90
Distributed vector processing of a new local multiscale Fourier transform for medical imaging applications. IEEE Trans Med Imaging (2005) 0.90
Magnetic resonance imaging of blood-spinal cord barrier disruption in mice with experimental autoimmune encephalomyelitis. Magn Reson Med (2007) 0.90
Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron deposition and demyelination. Mult Scler (2012) 0.89